Why is "Curium" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-06-11 00:21:18
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Curium entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-06-11 and was most recently seen on 2026-06-11.
Wikipedia Overview
Curium is a synthetic chemical element; it has symbol Cm and atomic number 96. This transuranic actinide element was named after eminent scientists Marie and Pierre Curie, both known for their research on radioactivity. Curium was first intentionally made by the team of Glenn T. Seaborg, Ralph A. James, and Albert Ghiorso in 1944, using the cyclotron at Berkeley. They bombarded the newly discovered element plutonium with alpha particles. This was then sent to the Metallurgical Laboratory at the University of Chicago where a tiny sample of curium was eventually separated and identified. The discovery was kept secret until after the end of World War II. The news was released to the public in November 1947. Most curium is produced by bombarding uranium or plutonium with neutrons in nuclear reactors – one tonne of spent nuclear fuel contains ~20 grams of curium.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency - BioSpace
-
LNTH Stock Drops After-Hours As Curium's $7B Offer Comes In Below Market Value - Stocktwits
-
Curium strikes up to $8B deal for radiopharma rival Lantheus - Fierce Biotech
-
Curium deepens radiopharma heft with up to $8 billion deal for Lantheus - Reuters
-
Curium strikes up to $8 billion deal for radiopharma peer Lantheus - CNBC
-
Curium Agrees to Acquire Radiopharmaceutical Company Lantheus in Deal Worth Up to $8 Billion - The Healthcare Technology Report.
-
Curium Announces Definitive Agreement to Merge with Lantheus - GlobeNewswire
-
Curium acquisition of Lantheus backed by $5.375B of debt financing - PitchBook
-
Curium reportedly closing in on deal to buy radiopharma rival Lantheus for $7B - Radiology Business
-
Radiopharma Lantheus mulling $7B takeout offer from Curium: report - FirstWord Pharma
-
Curium, Lantheus win patent dispute over lutetium-177 dotatate products - AuntMinnie
-
CVC Credit continues support for Curium through its Capital Solutions strategy - cvc.com
-
Curium strikes $8bn deal to buy radiopharma rival Lantheus - pharmaphorum
-
Thallium-201 returns to US market for cardiac imaging - Cardiovascular Business
-
Radiopharmaceutical outfit Lantheus mulls potential $7B takeover by Curium: Bloomberg - Fierce Pharma
-
Curium to buy Bedford-based Lantheus in deal worth up to $8B - The Business Journals
-
Lantheus Strikes Up to $8 Billion Go-Private Deal With Curium - Yahoo Finance
-
Curium reintroduces Tl-201 in the U.S. - AuntMinnie
-
Curium expands oncology pipeline as it acquires Belgian developer of cancer imaging agent - The Business Journals
-
Lantheus (LNTH) Agrees To Join Curium In Radiopharmaceuticals Deal - Yahoo Finance
-
Lantheus weighs potential $7 billion sale after Curium's offer, Bloomberg News reports - Yahoo Finance
-
Lantheus weighs potential $7 billion sale after Curium's offer, Bloomberg News reports - Reuters
-
Lantheus Holdings to Be Acquired for Initial $6.7 Billion - WSJ
-
Curium Knocks Out Novartis Cancer Drug Patents in Generics Fight - Bloomberg Law News
-
Curium to Take Lantheus Private in Deal Worth Up to $8 Billion - Bloomberg.com
-
Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology - GlobeNewswire
-
Curium Announces a Strategic Investment of Over €32 million in Saclay, France - GlobeNewswire
-
Lantheus Explores Potential $7 Billion Sale Following Offer From Curium - Bloomberg.com
-
Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan - GlobeNewswire
-
PE-backed Curium to acquire radiopharma biotech Lantheus for up to $8B - Axios
-
From Product to Patient in Nuclear Medicine: Why Vertical Integration Is Essential for a Competitive Advantage - BioSpace
-
Curium, in collaboration with nuclear cardiology leaders, announces immediate return of Thallous Chloride TI 201 Injection in the U.S. to support high-stakes cardiac imaging needs - GlobeNewswire
-
Lantheus weighs potential sale with $7B valuation - Radiology Business
-
Americium, curium and californium — oh my! Crystallizing the rarest elements at LLNL - Lawrence Livermore National Laboratory (.gov)
-
Curium acquires Abscint to expand its PET radiodiagnostic pipeline - Dealroom
-
The Merger of Radiopharmaceutical Pioneering Companies: Curium and Lantheus - Labroots
-
Curium court decision advances therapy plans for GEP-NETs - The Pharma Letter
-
Court victory paves the way for Curium’s plans to provide targeted radioligand therapy to U.S. patients with GEP-NETs - GlobeNewswire
-
B.Riley downgrades Lantheus stock rating on Curium acquisition - Investing.com
-
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan - GlobeNewswire
-
FutureChem ends Curium Austria deal to regain European prostate cancer imaging rights - Korea Biomedical Review
-
Curium acquires Abscint, adds HER2 PET tracer to oncology pipeline - DOTmed
-
Curium Consolidates New Biopharma Business and Sets Up Global Headquarters in Boston, Massachusetts - GlobeNewswire
-
CapVest recapitalizes Curium to accelerate its growth strategy, marking the largest transaction in nuclear medicine globally - Yahoo Finance
-
Radiopharmaceutical firm Curium to expand St. Louis-area operations - The Business Journals
-
Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026 - GlobeNewswire
-
PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of - Business Wire
-
Sabine Brookman-May: Starting a New Chapter as VP Global Head of Clinical Development at Curium Pharma - Oncodaily
-
Curium in talks to buy Lantheus Holdings for about $7B - Bloomberg (LNTH:NASDAQ) - Seeking Alpha
-
Curium to Buy Lantheus in Deal Worth Up to $8B - Briefs Finance
-
Jordan Johnson: The $8B Curium–Lantheus Merger Is About Infrastructure, Not Innovation - Oncodaily
-
Curium to buy Lantheus in radiopharma deal worth up to $8B - Dealroom
-
4 Firms Steer Curium's $8B Lantheus Take-Private Deal - Law360
-
Curium to Acquire Lantheus in $8 Billion Merger - Global Legal Chronicle
-
Curium to invest €32M in French radiopharmaceutical facility - AuntMinnieEurope
-
When physics meets antitrust: The CNMC’s move to block Curium–IRAB - White & Case LLP
-
Curium restores US supply of thallium 201 for nuclear cardiology imaging - DOTmed
-
CapVest sells Curium Pharma to continuation fund at $7B valuation - PitchBook
-
Lantheus (LNTH) Considers Sale Following Curium Acquisition Prop - GuruFocus
-
Americium, Curium and Californium — Oh My! Crystallizing the Rarest Elements at LLNL | Newswise - Newswise
-
Lantheus Holdings (LNTH) Evaluates $7 Billion Sale After Curium Offer - GuruFocus
-
Lantheus earnings in focus as investors weigh Curium merger deal By Investing.com - Investing.com
-
CNMC Merger Prohibition: Spain Blocks Curium/IRAB Acquisition - A&O Shearman
-
ICG, TPG and CVC back latest mammoth CV-on-CV deal - PEI Secondaries Investor
-
Scaling Radioligand Therapy: Expanding the Impact of Theranostics - Fierce Biotech
-
French radiopharmaceutical firm sites 'global HQ' in Boston, and other life science news - The Business Journals
-
Boston’s Next Life Sciences Wave: Building the Infrastructure Behind Theranostics - The Business Journals
-
Prostate Cancer Updates From ASCO 2026 - Medscape
-
Curium buys Lantheus for $8B; Sandoz settles price-fixing cases - Endpoints News
-
Curium Is Said To Near About $7 Billion Acquisition Of Lantheus - Bloomberg News - TradingView
-
CapVest closes CV for nuclear medicine firm Curium - pehub.com
-
Curium invests EUR 32M in Saclay radiopharmaceuticals - AllSci
-
Curium Transformative Cancer Therapy: Expanding Radioligand Treatment to Revolutionise Oncology - The European Magazine
-
Clifford Chance advises ICG Strategic Equity as Lead on CapVest's GP-led recapitalisation of Curium - Clifford Chance
-
PeptiDream, PDRadiopharma, and Curium Launch Registrational Phase 2 Trial in Japan for 64Cu-PSMA-I&T Targeting Prostate Cancer - BioPharma APAC
-
Curium advances plans for second investment in Romania to expand access to advanced nuclear medicine - The Manila Times
-
Incredible GLOBE40 Leg 4 Finish: Seconds split Belgium Ocean Racing - Curium and Credit Mutuel - Sail-World.com
-
Novartis Adds New Patent to Curium Fight Over Cancer Drug - Bloomberg Law News
-
Curium to acquire Lantheus in $8B deal, offerin... - Pluang
-
Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology - The Manila Times
-
Partnering To Commercialize Radiopharmaceuticals - Life Science Leader
-
Curium Life: AI platform for surgical intelligence - YourStory.com
-
Curium to acquire Lantheus in $8B deal, expandi... - Pluang
-
Incredible GLOBE40 Leg 4 Finish: Seconds split Belgium Ocean Racing - Curium and Credit Mutuel - Sail-World.com
-
Curium, in collaboration with nuclear cardiology leaders, announces immediate return of Thallous Chloride TI 201 Injection in the U.S. to support high-stakes cardiac imaging needs - The Manila Times
-
TPG scoops up Pike from Lindsay Goldberg; CapVest completes CV for Curium; CAI Capital seeks add-ons for GreenArrow - pehub.com
-
Curium Announces Definitive Agreement to Merge with Lantheus - The Manila Times
-
CapVest Upstages PE Titans With $3.8 Billion Continuation Fund - Bloomberg.com
-
France: CapVest recapitalises Curium to accelerate growth strategy - Investors in Healthcare
-
Globe40 2025/26 Stage 2 Update - Belgium Ocean Racing - Curium and Credit Mutuel 1 mile apart - Sail-World.com
-
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan - Macau Business
-
Curium Establishes Legal Entity in China - Macau Business
-
Probing the subtle differences between promethium and curium - Nature
-
Ariane 6 launches Curium One: space for all - European Space Agency
-
A New Look for Curium Under High Pressure? Rediscovering the Radioactive Element - DongA Science
-
Altering the spectroscopy, electronic structure, and bonding of organometallic curium(III) upon coordination of 4,4′−bipyridine - Nature
-
Lantheus Holdings (NASDAQ:LNTH) in Focus as Curium Deal Stirs Radiopharma - Kalkine Media
-
Lantheus Holdings Just Became The $7 Billion Radiopharma Target Everyone Is Watching! - Smartkarma
-
ECLIPSE trial: 177Lu-PSMA-I&T extends rPFS vs hormone therapy in mCRPC - Urology Times
-
Curium signs cooperation agreement with Dazhou, China - Cyprus Mail
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.